A randomized clinical trial from the University of Pisa, published in Clinical Oral Implants Research in November 2026, tested whether adding a volume-stable collagen matrix for buccal soft tissue augmentation changes outcomes around immediate implants in the esthetic zone. At 12 months, the sites that received the matrix had thicker peri-implant soft tissue, a stable mucosal level and no significant volume loss, while the sites without it showed significant recession and shrinkage. Marginal bone level did not change significantly over time in either group.
Immediate implant placement in the anterior maxilla is a balancing act. Your patient wants one surgery and a fast result; the buccal soft tissue needs time. As of November 2026, a new randomized clinical trial adds data to one of the most practical questions in that workflow: does adding a soft tissue substitute at the time of immediate placement change what the mucosa looks like a year later?
The trial, by Cinquini, Baldi, Izzetti, Simonini, Buti and Barone, was published online on November 5, 2026 in Clinical Oral Implants Research (November 2026 issue). This summary is based on the published abstract and the study's public registration on ClinicalTrials.gov. EBIKO Dental reports it here for dentists and periodontists in Toronto and across Ontario who place or restore immediate implants.
What Did the Trial Compare?
This was not a comparison of grafting against no grafting. According to the study registration, every participant received an immediate implant in a fresh extraction site, and in both groups the peri-implant bone defect was grafted with deproteinized bovine bone mineral with 10% collagen and covered with a collagen matrix.
The difference was one added step. In the test group, a volume-stable collagen matrix (abbreviated VCMX in the paper) was also inserted on the buccal side using a split-thickness flap and stabilized with a horizontal mattress suture. The control group did not receive that buccal soft tissue augmentation. The registration lists the test intervention as the volume-stable collagen matrix Geistlich Fibro-Gide.
The trial was sponsored by the University of Pisa, and its registered study site is in Pisa, Italy. According to the registration, it was single-blinded (investigator), with an estimated enrolment of 40 participants, and began on January 10, 2022. The abstract reports that 38 of 40 patients completed the study.
Who was eligible?
The registration describes a selective population, which matters when you decide how far to apply the findings to your own patients:
- A single failing tooth in the esthetic region, from second premolar to contralateral second premolar, with adjacent teeth present and free of dental pathology
- No heavy smokers (more than 10 cigarettes a day)
- No systemic disease that could impair wound healing, no head and neck radiation, and no full contraindication to implant surgery
- No uncontrolled periodontal disease, and full-mouth plaque and bleeding scores no higher than 25%
- No deficient extraction sockets under the Juodzbalys and colleagues (2008) classification
- No known allergy, sensitivity or intolerance to collagen, and no pregnancy or breastfeeding
In short, the results describe patients without deficient sockets, without systemic conditions affecting healing, and with good plaque and bleeding control. That is a favourable scenario for immediate placement.
How was soft tissue thickness measured?
Soft tissue thickness was the primary outcome. The registration describes measuring it at 3 mm and 6 mm from the free gingival margin by passing a size 15 endodontic file with a rubber stop through the tissue until it contacted bone, then reading the depth with a caliper. The abstract reports assessments before surgery, immediately after surgery, and at 6 and 12 months.
What Did the Trial Find at 12 Months?
The authors report that soft tissue thickness was significantly greater in the test group at every follow-up. The within-group changes at 12 months add detail:
- Test group (with the buccal matrix): soft tissue thickness increased significantly at 3 mm from the gingival margin (1.85 mm, SE 0.19) and increased at 6 mm (1.29 mm, SE 0.24), although the 6 mm change was not statistically significant.
- Control group (without it): soft tissue thickness decreased at 3 mm (0.18 mm, SE 0.18) and at 6 mm (0.36 mm, SE 0.10). Neither decrease was statistically significant.
The secondary outcomes point in the same direction. The mucosal level stayed stable in the test group but showed significant recession in the control group. Volumetric analysis found no significant change over time in the test group and significant shrinkage in the control group. The authors also report that selected esthetic and patient-reported outcomes favoured the test group.
Marginal bone level did not change significantly over time in either group, according to the abstract.
Pro Tip: When you read soft tissue graft studies, note where thickness was measured. This trial reports separate results at 3 mm and 6 mm from the margin, and in the test group only the within-group change at 3 mm reached significance. The tissue nearest the margin is the tissue your patient sees.
How Should Ontario Clinicians Read These Results?
The authors' own conclusion is measured: augmentation with the matrix "may improve soft tissue stability around immediate implants." That wording is appropriate for a trial of this size, and it is the right frame for your treatment planning conversations too.
What the trial supports
For patients like those enrolled, with immediate implants and bone grafting in the esthetic zone, the trial adds randomized evidence that a buccal volume-stable collagen matrix may help maintain mucosal level and soft tissue volume over 12 months. Between groups, soft tissue thickness was significantly greater in the test group at every follow-up; within the control group, the loss of thickness was not statistically significant, while mucosal recession and volume shrinkage were.
What the trial does not tell you
- Long-term stability. The paper reports 12 months. The registration lists follow-up out to 36 months and an estimated completion date of December 31, 2027, so longer data may follow.
- Comparison with autogenous grafts. The trial compared the matrix with no buccal soft tissue augmentation. It does not compare it with a connective tissue graft, a common alternative.
- Higher-risk patients. Heavy smokers (more than 10 cigarettes a day), patients with deficient sockets and patients with uncontrolled periodontal disease were excluded, so the results cannot be extended to them.
- Cost. The abstract does not report cost-effectiveness. Surgery time was a registered secondary outcome but is not reported in the abstract.
Canadian regulatory and supply considerations
The trial was conducted in Italy, and neither the abstract nor the registration addresses Canadian availability. Before you use any bone substitute or soft tissue matrix named in an international study, confirm that the specific product is licensed by Health Canada as a medical device and is available through your supplier in Canada. Product names and approved indications can differ between markets.
Pro Tip: If you are adding a soft tissue substitute to your immediate implant protocol, update your informed consent discussion to cover what the material is made from (check the product labelling for its source), the alternative of an autogenous graft, and the option of no soft tissue graft. A known collagen allergy was an exclusion criterion in this trial for good reason.
Where This Fits for Practices in the GTA
Whether you place implants in Mississauga or restore them in Markham, trials like this one help move soft tissue decisions from preference toward evidence, but each study answers a narrow question. This one shows what adding a buccal collagen matrix did, compared with no buccal soft tissue augmentation, in a selected group of patients at 12 months. It is a useful data point, not a protocol.
EBIKO Dental will continue monitoring the implant and periodontal literature and will report the longer follow-up from this trial if it is published. For practical supply guides and clinical news for Canadian practices, visit EBIKO Dental.
Sources
- Cinquini C, Baldi N, Izzetti R, Simonini R, Buti J, Barone A. Immediate Implants With or Without a Volume Stable Collagen Matrix: A Randomized Clinical Trial. Clinical Oral Implants Research, November 2026. DOI: 10.1111/clr.70199 (Europe PMC record)
- ClinicalTrials.gov: NCT05081284, Clinical Outcomes of Immediate Implants With or Without a Volume-stable Collagen Matrix
Frequently Asked Questions
Q: Does a collagen matrix improve soft tissue around immediate implants?
It may. In a 2026 randomized trial from the University of Pisa, immediate implants that received a buccal volume-stable collagen matrix, on top of bone grafting, had significantly thicker soft tissue at 12 months than implants without the matrix. The authors conclude the matrix "may improve soft tissue stability"; sites without it showed significant recession and volume shrinkage.
Q: Did the collagen matrix change bone levels around the implants?
The abstract reports that marginal bone level did not change significantly over time in either group. Both groups received the same bone graft; the added matrix was for soft tissue augmentation.
Q: Can Canadian dentists use the matrix from this study?
The study does not address Canadian availability. Confirm that any soft tissue substitute is licensed by Health Canada and available from your Canadian supplier before using it, and discuss the alternatives, including an autogenous graft, with your patient.
